| Literature DB >> 27693414 |
Andres Asser1, Sulev Kõks2, Anniina Snellman3, Merja Haaparanta-Solin3, Eveliina Arponen3, Tove Grönroos3, Jaak Nairismägi4, Jonas Bergquist5, Ursel Soomets6, Piret Piip1, Mall Eltermaa1, Martin Sauk1, Hanna Lindmäe1, Juha O Rinne7, Pille Taba8.
Abstract
Intravenous use of a psychostimulant drug containing methcathinone (ephedrone) and manganese causes an irreversible extrapyramidal syndrome in drug abusers. We aimed to reproduce the syndrome in mice to evaluate dopaminergic damage. C57/B6 mice were intraperitoneally injected once a day with the study drug or saline for a period of 27 weeks. Motor activity was recorded in an automated motility-box. After 13 and 27 weeks of treatment, ex vivo digital autoradiography was performed using [11C]dihydrotetrabenazine ([11C]DTBZ). After 27 weeks of treatment [11C]DTBZ autoradiography demonstrated a significant increase in the striatum-to-cerebellum binding ratio compared with saline treated controls. At the same time point, there was no evident change in motor activity. Increased [11C]DTBZ binding may indicate vesicular monoamine transporter type 2 (VMAT2) function is altered. The lack of extrapyramidal symptoms in animals could be attributed to low dosing regimen or high metabolic rate.Entities:
Keywords: Ephedrone; Manganism; Methcathinone; PET; VMAT2
Mesh:
Substances:
Year: 2016 PMID: 27693414 DOI: 10.1016/j.brainres.2016.09.034
Source DB: PubMed Journal: Brain Res ISSN: 0006-8993 Impact factor: 3.252